We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 30, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Goldman Sachs Group, Inc. (GS - Free Report) , RTX Corp. (RTX - Free Report) , Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Optex Systems Holdings, Inc (OPXS - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Goldman Sachs, RTX and Regeneron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc., RTX Corp. and Regeneron Pharmaceuticals, Inc., as well as a micro-cap stock Optex Systems Holdings, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Goldman Sachs have outperformed the Zacks Financial - Investment Bank industry over the past six months (+29.0% vs. +18.4%). The company’s second-quarter results reflected improved capital ratios and lower provisions. Goldman Sachs’ refocus on the core strengths of IB and trading businesses through restructuring initiatives and opportunistic buyouts will boost its presence in overseas markets.
Improvement in global deal-making and underwriting activities and Goldman’s leading position will likely support IB revenue growth. The bank’s decent liquidity position will aid capital distribution moves.
Yet, its global banking & markets division will likely be under pressure due to the volatile nature of capital markets and uncertainty in client volumes. A rise in costs will likely hinder its bottom line. Given the current geopolitical concerns, high dependence on overseas revenues remains a woe.
RTX shares have outperformed the Zacks Aerospace - Defense industry over the past year (+29.6% vs. -5.1%). The company’s ended second-quarter 2024 on a solid note, with both its revenues and earnings having surpassed their respective Zacks Consensus Estimate. It continues to receive ample orders for its wide range of combat-proven defense products.
A steadily recovering commercial air traffic has been bolstering commercial OEM as well as commercial aftermarket sales for the company. RTX holds a solid financial position, which enables it to make successful share repurchases.
However, rising crude price tends to put cost pressure on airlines that may affect the operating results of commercial OEM producers like RTX. The company may also be affected if China enforces its announced sanctions against its missile and defense unit. Supply-chain challenges also pose a threat to RTX.
Shares of Regeneron have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+45.4% vs. -2.0%). The company’s lead drug Eylea's sales have been under pressure due to competition from Roche’s Vabysmo. To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug.
The initial uptake of Eylea HD is encouraging as Eylea patients transition to the higher dose. However, it may be a while before the higher dose can compensate for the loss incurred in Eylea sales.
Nonetheless, Dupixent maintains momentum, driven by growing demand in the approved indications of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. The approval of Libtayo has diversified the portfolio. The bottom-line estimate has increased ahead of the second-quarter results.
Optex Systems shares have outperformed the Zacks Aerospace - Defense Equipment industry over the year-to-date period (+22.7% vs. +15.9%). This microcap company with market capitalization of $ 54.69 million shows promising investment prospects due to a robust order backlog exceeding $47 million, ensuring a steady revenue stream through mid-2025. Key contracts include laser-protected periscopes and optical assemblies for military applications.
Optex Systems’ commitment to technological innovation, evident in advanced products like Laser Interference Filter assemblies, positions it well in the rapidly evolving defense sector. Financially, Optex has improved, with net income rising to $1.5 million in the first half of 2024, indicating effective cost and resource management. Strategic relationships with defense contractors enhance its market stability and growth potential.
However, potential defense budget cuts, supply chain disruptions, and high customer concentration pose risks. Loss of major clients or reduced defense spending could impact revenues.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems
For Immediate Release
Chicago, IL – July 30, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Goldman Sachs Group, Inc. (GS - Free Report) , RTX Corp. (RTX - Free Report) , Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Optex Systems Holdings, Inc (OPXS - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Goldman Sachs, RTX and Regeneron
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc., RTX Corp. and Regeneron Pharmaceuticals, Inc., as well as a micro-cap stock Optex Systems Holdings, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Goldman Sachs have outperformed the Zacks Financial - Investment Bank industry over the past six months (+29.0% vs. +18.4%). The company’s second-quarter results reflected improved capital ratios and lower provisions. Goldman Sachs’ refocus on the core strengths of IB and trading businesses through restructuring initiatives and opportunistic buyouts will boost its presence in overseas markets.
Improvement in global deal-making and underwriting activities and Goldman’s leading position will likely support IB revenue growth. The bank’s decent liquidity position will aid capital distribution moves.
Yet, its global banking & markets division will likely be under pressure due to the volatile nature of capital markets and uncertainty in client volumes. A rise in costs will likely hinder its bottom line. Given the current geopolitical concerns, high dependence on overseas revenues remains a woe.
(You can read the full research report on Goldman Sachs here >>>)
RTX shares have outperformed the Zacks Aerospace - Defense industry over the past year (+29.6% vs. -5.1%). The company’s ended second-quarter 2024 on a solid note, with both its revenues and earnings having surpassed their respective Zacks Consensus Estimate. It continues to receive ample orders for its wide range of combat-proven defense products.
A steadily recovering commercial air traffic has been bolstering commercial OEM as well as commercial aftermarket sales for the company. RTX holds a solid financial position, which enables it to make successful share repurchases.
However, rising crude price tends to put cost pressure on airlines that may affect the operating results of commercial OEM producers like RTX. The company may also be affected if China enforces its announced sanctions against its missile and defense unit. Supply-chain challenges also pose a threat to RTX.
(You can read the full research report on RTX here >>>)
Shares of Regeneron have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+45.4% vs. -2.0%). The company’s lead drug Eylea's sales have been under pressure due to competition from Roche’s Vabysmo. To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug.
The initial uptake of Eylea HD is encouraging as Eylea patients transition to the higher dose. However, it may be a while before the higher dose can compensate for the loss incurred in Eylea sales.
Nonetheless, Dupixent maintains momentum, driven by growing demand in the approved indications of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. The approval of Libtayo has diversified the portfolio. The bottom-line estimate has increased ahead of the second-quarter results.
(You can read the full research report on Regeneron here >>>)
Optex Systems shares have outperformed the Zacks Aerospace - Defense Equipment industry over the year-to-date period (+22.7% vs. +15.9%). This microcap company with market capitalization of $ 54.69 million shows promising investment prospects due to a robust order backlog exceeding $47 million, ensuring a steady revenue stream through mid-2025. Key contracts include laser-protected periscopes and optical assemblies for military applications.
Optex Systems’ commitment to technological innovation, evident in advanced products like Laser Interference Filter assemblies, positions it well in the rapidly evolving defense sector. Financially, Optex has improved, with net income rising to $1.5 million in the first half of 2024, indicating effective cost and resource management. Strategic relationships with defense contractors enhance its market stability and growth potential.
However, potential defense budget cuts, supply chain disruptions, and high customer concentration pose risks. Loss of major clients or reduced defense spending could impact revenues.
(You can read the full research report on Optex Systems here >>>)
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.